Immune to Cancer: The CRI Blog



Brain Cancer Awareness Month: 2022 Immunotherapy Research Updates

CRI Impact Grantee Robert Michael Angelo, MD, PhD, of Stanford University led the development of a new way to conduct in-depth analysis of the biology and spatial relationships of cells within brain tumors. By constructing TissueNet, a dataset for training models, and Mesmer, a deep-learning algorithm, Dr. Angelo’s tools might reveal new approaches to brain cancer immunotherapy.

This May, for Brain Cancer Awareness Month, discover new research, new treatments, and progress for a future immune to cancers of the brain and nervous system.

Brain Cancer Treatment Update

At the CRI Virtual Immunotherapy Patient Summit last October, Dr. David Reardon of Dana-Farber Cancer Institute discussed new immunotherapies and combination therapies in clinical trials.

Overcoming Neuro-Immune Dysfunction 

We spoke with CRI Lloyd J. Old STAR Dr. Peter Fecci at Duke University about how his research is uncovering brain cancer’s defensive tactics to reveal potential new treatment approaches. 

Brain Cancer Patient Story

After her third brain surgery, Jeannine entered a clinical trial for a personalized dendritic cell vaccine, a type of immunotherapy. 

Meet Jeannine

Brain Cancer Scientist Spotlight

CRI-V Foundation CLIP Investigator Dr. Adilia Hormigo is using cutting-edge technologies to analyze the molecular mechanisms of the immuno-suppressive tumor microenvironment in glioblastoma.

Read Glioblastoma Research

Immunotherapy for Brain Cancer

Cancers of the brain and nervous system are relatively rare but very serious. Immunotherapy is showing significant promise where other approaches have failed, including in glioblastoma.

READ Brain Cancer UPDATE

Find a Clinical Trial

Help speed the development of potentially lifesaving drugs. Discover trials for which you or a loved one may be eligible with the CRI Immunotherapy Clinical Trial Finder.

FIND A Cancer Clinical TRIAL 

Support Brain Cancer Research

CRI-Thompson Family Foundation CLIP Investigator Robert M. Prins, PhD, of UCLA recently led a study that shows immune checkpoint therapy temporarily slows glioblastoma progression but fails to establish an effective anti-tumor microenvironment and appears to increase molecular interactions inhibiting long-term immune response. These insights will help scientists develop new strategies to create more effective immunotherapies in future. This Brain Cancer Awareness Month, support lifesaving cancer immunotherapy research.

DONATE to brain cancer research

Read more:

This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.